113 related articles for article (PubMed ID: 20629576)
1. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women.
Zimmerman RK; Nowalk MP; Lin CJ; Fox DE; Ko FS; Wettick E; Cost G; Hand L; Hayes J; Michaels M
J Womens Health (Larchmt); 2010 Aug; 19(8):1441-7. PubMed ID: 20629576
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
[TBL] [Abstract][Full Text] [Related]
3. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
Iversen OE; Miranda MJ; Ulied A; Soerdal T; Lazarus E; Chokephaibulkit K; Block SL; Skrivanek A; Nur Azurah AG; Fong SM; Dvorak V; Kim KH; Cestero RM; Berkovitch M; Ceyhan M; Ellison MC; Ritter MA; Yuan SS; DiNubile MJ; Saah AJ; Luxembourg A
JAMA; 2016 Dec; 316(22):2411-2421. PubMed ID: 27893068
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males.
Lin CJ; Zimmerman RK; Nowalk MP; Huang HH; Raviotta JM
Vaccine; 2014 Feb; 32(6):693-9. PubMed ID: 24342252
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
Lamontagne DS; Thiem VD; Huong VM; Tang Y; Neuzil KM
J Infect Dis; 2013 Oct; 208(8):1325-34. PubMed ID: 23901077
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
Dobson SR; McNeil S; Dionne M; Dawar M; Ogilvie G; Krajden M; Sauvageau C; Scheifele DW; Kollmann TR; Halperin SA; Langley JM; Bettinger JA; Singer J; Money D; Miller D; Naus M; Marra F; Young E
JAMA; 2013 May; 309(17):1793-802. PubMed ID: 23632723
[TBL] [Abstract][Full Text] [Related]
8. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months.
Lazcano-Ponce E; Stanley M; Muñoz N; Torres L; Cruz-Valdez A; Salmerón J; Rojas R; Herrero R; Hernández-Ávila M
Vaccine; 2014 Feb; 32(6):725-32. PubMed ID: 24355090
[TBL] [Abstract][Full Text] [Related]
9. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
[TBL] [Abstract][Full Text] [Related]
10. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial.
Donken R; Dobson SRM; Marty KD; Cook D; Sauvageau C; Gilca V; Dionne M; McNeil S; Krajden M; Money D; Kellner J; Scheifele DW; Kollmann T; Bettinger JA; Liu S; Singer J; Naus M; Sadarangani M; Ogilvie GS
Clin Infect Dis; 2020 Aug; 71(4):1022-1029. PubMed ID: 31617568
[TBL] [Abstract][Full Text] [Related]
12. Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals.
Russell K; Dunne EF; Kemper AR; Dolor RJ; Unger ER; Panicker G; Markowitz LE; Walter EB
Vaccine; 2015 Apr; 33(16):1953-8. PubMed ID: 25744229
[TBL] [Abstract][Full Text] [Related]
13. Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine.
Bornstein J; Roux S; Kjeld Petersen L; Huang LM; Dobson SR; Pitisuttithum P; Diez-Domingo J; Schilling A; Ariffin H; Tytus R; Rupp R; Senders S; Engel E; Ferris D; Kim YJ; Tae Kim Y; Kurugol Z; Bautista O; Nolan KM; Sankaranarayanan S; Saah A; Luxembourg A
Pediatrics; 2021 Jan; 147(1):. PubMed ID: 33386332
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers.
Brown B; Blas M; Cabral A; Carcamo C; Gravitt P; Halsey N
Vaccine; 2012 Mar; 30(13):2309-14. PubMed ID: 22306855
[TBL] [Abstract][Full Text] [Related]
16. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and Safety of a 9-Valent HPV Vaccine.
Van Damme P; Olsson SE; Block S; Castellsague X; Gray GE; Herrera T; Huang LM; Kim DS; Pitisuttithum P; Chen J; Christiano S; Maansson R; Moeller E; Sun X; Vuocolo S; Luxembourg A
Pediatrics; 2015 Jul; 136(1):e28-39. PubMed ID: 26101366
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
[TBL] [Abstract][Full Text] [Related]
19. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
Luxembourg A; Brown D; Bouchard C; Giuliano AR; Iversen OE; Joura EA; Penny ME; Restrepo JA; Romaguera J; Maansson R; Moeller E; Ritter M; Chen J
Hum Vaccin Immunother; 2015; 11(6):1313-22. PubMed ID: 25912208
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination.
Palmroth J; Merikukka M; Paavonen J; Apter D; Eriksson T; Natunen K; Dubin G; Lehtinen M
Int J Cancer; 2012 Dec; 131(12):2832-8. PubMed ID: 22492244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
